BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaya E, Yılmaz Y. Non-alcoholic fatty liver disease: A growing public health problem in Turkey. Turk J Gastroenterol 2019;30:865-71. [PMID: 31258135 DOI: 10.5152/tjg.2019.18045] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol 2021;15:345-52. [PMID: 33270482 DOI: 10.1080/17474124.2021.1860019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
2 Golabi P, Paik JM, AlQahtani S, Younossi Y, Tuncer G, Younossi ZM. Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019. J Hepatol 2021:S0168-8278(21)00358-5. [PMID: 34081959 DOI: 10.1016/j.jhep.2021.05.022] [Reference Citation Analysis]
3 Alkayyali T, Qutranji L, Kaya E, Bakir A, Yilmaz Y. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease. Acta Diabetol 2020;57:613-8. [PMID: 31897769 DOI: 10.1007/s00592-019-01467-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
4 Tahtabasi M, Hosbul T, Karaman E, Akin Y, Kilicaslan N, Gezer M, Sahiner F. Frequency of hepatic steatosis and its association with the pneumonia severity score on chest computed tomography in adult COVID-19 patients. World J Crit Care Med 2021; 10(3): 47-57 [PMID: 34046310 DOI: 10.5492/wjccm.v10.i3.47] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Koç U, Taydaş O. Evaluation of pancreatic steatosis prevalence and anthropometric measurements using non-contrast computed tomography. Turk J Gastroenterol 2020;31:640-8. [PMID: 33090101 DOI: 10.5152/tjg.2020.19434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zheng KI, Fan JG, Shi JP, Wong VW, Eslam M, George J, Zheng MH. From NAFLD to MAFLD: a "redefining" moment for fatty liver disease. Chin Med J (Engl) 2020;133:2271-3. [PMID: 32701591 DOI: 10.1097/CM9.0000000000000981] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 21.0] [Reference Citation Analysis]
7 Demir N, Ekin N, Torgutalp M, Wahlin S, Efe C. Two decades of research on autoimmune liver disease in Turkey. Turk J Gastroenterol 2020;31:877-82. [PMID: 33626000 DOI: 10.5152/tjg.2020.19866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Hamurcu Varol P, Kaya E, Alphan E, Yilmaz Y. Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients. Eur J Gastroenterol Hepatol. 2020;32:1352-1357. [PMID: 32092046 DOI: 10.1097/meg.0000000000001656] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
9 Ryou M, Stylopoulos N, Baffy G. Nonalcoholic fatty liver disease and portal hypertension. Explor Med 2020;1:149-69. [PMID: 32685936 DOI: 10.37349/emed.2020.00011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
10 Tang L, Ma H, Eslam M, Wong GL, Zhu P, Chen S, Leeming DJ, Karsdal M, Li G, Huang O, Leung HH, Zhou Y, Feng Q, Jiang P, Gao L, Byrne CD, Targher G, George J, Wong VW, Zheng M. Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. Metabolism 2022;128:154958. [DOI: 10.1016/j.metabol.2021.154958] [Reference Citation Analysis]